Sanofi keeps nipping at J&J’s heels as Sarclisa notches new FDA approval in multiple myeloma

The multiple myeloma rivalry between Sanofi and J&J continued Wednesday evening, with the French drugmaker’s Sarclisa taking home a new approval in the indication.

US regulators OK’d the drug in combination with Amgen’s Kyprolis and the steroid dexamethasone for adults with relapsed or refractory multiple myeloma who have received between...

Click to view original post